Ontology highlight
ABSTRACT:
SUBMITTER: Khair NZ
PROVIDER: S-EPMC6511963 | biostudies-literature | 2019 May
REPOSITORIES: biostudies-literature
ACS medicinal chemistry letters 20190320 5
Specific abrogation of cyclin-dependent kinase 5 (CDK5) activity has been validated as a viable approach for the development of anticancer agents. However, no selective CDK5 inhibitor has been reported to date. Herein, a structure-based <i>in silico</i> screening was employed to identify novel scaffolds from a library of compounds to identify potential CDK5 inhibitors that would be relevant for drug discovery. Hits, representatives of three chemical classes, were identified as inhibitors of CDK5 ...[more]